Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2024-04-15 Proxy Solicitation & In…
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to the Securities Exchange Act of 1934. The text explicitly states it is a 'Definitive Additional Materials' related to a proxy statement for ADMA BIOLOGICS, INC. Proxy statements and related materials are classified under 'Proxy Solicitation & Information Statement' (PSI). The document length is short (1200 characters), and it is not a full report but additional materials related to proxy solicitation. Therefore, the correct classification is PSI with high confidence.
2024-04-15 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-15 English
FORM 4
Director's Dealing
2024-04-03 English
FORM 4
Director's Dealing
2024-04-03 English
FORM 3
Director's Dealing
2024-04-03 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 1, 2024, reporting the promotion of Kaitlin Kestenberg to Chief Operating Officer and Senior Vice President, Compliance. It details her employment agreement, compensation, and stock option grants. The content focuses on a change in senior management personnel and related agreements. There are no financial statements or earnings data, nor is this a report of voting results or a regulatory compliance filing unrelated to management changes. The primary subject is the appointment and promotion of an officer, which fits the category of Board/Management Information (MANG). The document length (11,354 characters) supports it being a substantive filing rather than a brief announcement. Therefore, the correct classification is MANG with high confidence.
2024-04-02 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.